Most of the melanoma patients with the BRAF mutation carry the BRAF V600E mutation, and these patients can be treated with BRAF-targeted therapy (e.g., vemurafenib, dabrafenib) in combination with MEK inhibitors (e.g., trametinib, cobimetinib) [3]. Here, MAP2K7 is linked to melanoma.